Trading on AIM

Provexis PLC
24 June 2005


24th June 2005
                                        
                                  PROVEXIS PLC
                                        
                         COMMENCEMENT OF TRADING ON AIM

Further to the announcement by Nutrinnovator Holdings plc on 23rd June 2005, 
Provexis plc ('Provexis' or the 'Company') AIM: PXS.L, announces the 
commencement of trading in its ordinary shares on AIM today.

• Provexis (originally founded in 1999) is a nutraceutical company which
develops scientifically-proven and proprietary functional foods, supplements
and medical foods. Functional foods are foods which are consumed for the
maintenance of health and have the potential to carry health claims to this
effect.


• Its lead technology is to be branded Fruitflow. Fruitflow, which was 
developed by Provexis under the name CardioFlow, is a proprietary extract of 
tomato, industrially produced to laboratory-determined specifications.
Fruitflow contains a range of tomato-derived components which inhibit platelet 
aggregation, a part of the blood-clotting process which can cause heart attack 
and stroke.


• The first commercially available product containing Fruitflow will be a fruit
juice drink called Sirco. The Company is in discussions with major high-street 
retailers and multiple grocers to secure distribution channels for Sirco and 
aims to launch it in two major UK retailers in the final quarter of calendar 
2005.


• In addition to Fruitflow, Provexis has a promising technology pipeline 
including a medical food for the dietary management of inflammatory bowel 
disease, specifically Chrohn's and a novel functional food product which is
expected to show risk reduction in a number of cancers.


• Provexis has raised approximately £3.8 million (before expenses) via a placing
at 5.6p per ordinary share and has converted £2.1 million of loans into new 
equity.


• The proceeds of the Placing will be used to launch and market Sirco in the UK 
and to continue to develop its near term product pipeline.


• Arbuthnot Securities is the nominated advisor and broker.


Dr Stephen Franklin, Chief Executive Officer of Provexis, said: 'The conclusion
of our reverse take-over of Nutrinnovator and our listing on AIM is an important
milestone in the development of the Company.

We believe we have a clearly differentiated position in the functional food
industry as our innovative functional food products have health benefits that
are scientifically-proven and therefore have the potential to carry credible
health claims and endorsements. This, combined with our proven speed-to-market
credentials, positions us well in the rapidly growing functional food market.'


                                      Ends
                                        

Provexis plc
Dr Stephen Franklin, CEO                         07710 348 774

Arbuthnot Securities Limited
Tom Griffiths                                    020 7012 2000

Bell Pottinger Corporate and Financial
Ann-Marie Wilkinson/Emma Kent                    020 7861 3232




                      This information is provided by RNS
            The company news service from the London Stock Exchange